AVP and metabolic syndrome: In our original study, after HYPO, AVP (as measured by copeptin) was elevated to levels seen in those with type 2 diabetes and the metabolic syndrome [23,24], with no difference in FGF21, yet again highlighting the unidirectionality of this relationship compared to the rodent literature.